YKL-06-061 (YKL06-061) is a novel and potent SIK (salt-inducible kinase) inhibitor (IC50: 6.56 nM/1.77 nM/20.5 nM (SIK1/2/3)) with the potential to be used as a dermatologic drug impacting UV protection and skin cancer risk. It causes a dose-dependent increase in microphthalmia-associated transcription factor (MITF) mRNA expression during 3-hour function in normal human melanocytes, UACC62 human melanoma cells, and UACC257 human melanoma cells.

纯度：≥98%

CAS：2172617-15-9